Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation & Amortization (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Accumulated Depreciation & Amortization data on record, last reported at $3.9 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 39.29% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, up 39.29%, while the annual FY2025 figure was $3.9 million, 39.29% up from the prior year.
  • Accumulated Depreciation & Amortization reached $3.9 million in Q4 2025 per CRNX's latest filing, down from $9.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $9.6 million in Q2 2025 and bottomed at $1.1 million in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $4.5 million, with a median of $3.9 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: crashed 73.07% in 2023, then soared 154.55% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.5 million in 2021, then grew by 17.36% to $4.1 million in 2022, then plummeted by 73.07% to $1.1 million in 2023, then skyrocketed by 154.55% to $2.8 million in 2024, then soared by 39.29% to $3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $3.9 million in Q4 2025, $9.6 million in Q2 2025, and $2.8 million in Q4 2024.